Boston Scientific Corporation
BSX
Ранг среди акций
#409
Это описание компании доступно только на английском языке.
Boston Scientific Corporation (BSX) operates as a global leader in medical... Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
Цена акции
$41.88
Последняя синхронизация: 2026-10-30
Рыночная капитализация
$60.69B
Изменение (1 день)
-1.89%
Изменение (1 год)
-58.42%
Страна
US
Данные по акциям: Financial Modeling Prep·Обновлено ·Не является инвестиционной рекомендацией·Как мы считаем
Торговля Boston Scientific Corporation (BSX)
Категория
Healthcare
EPS для Boston Scientific Corporation (BSX)
EPS по состоянию на September 2026 TTM: $2.37
Согласно последним финансовым отчетам и цене акций Boston Scientific Corporation, текущий EPS компании (TTM) составляет $2.37. В конце 2025 EPS компании составлял $1.96, больше, чем показателю 2024 года, равному $1.26.
История EPS компании Boston Scientific Corporation с 2000 по 2026
EPS на конец каждого года
| Год | EPS | Изменение |
|---|---|---|
| 2026 (TTM) | $2.37 | 20.92% |
| 2025 | $1.96 | 55.56% |
| 2024 | $1.26 | 16.61% |
| 2023 | $1.08 | 140.75% |
| 2022 | $0.45 | -35.19% |
| 2021 | $0.69 | -952.83% |
| 2020 | $-0.08 | -102.40% |
| 2019 | $3.38 | 179.14% |
| 2018 | $1.21 | 1,412.50% |
| 2017 | $0.08 | -69.23% |
| 2016 | $0.26 | -244.44% |
| 2015 | $-0.18 | 100.00% |
| 2014 | $-0.09 | 0.00% |
| 2013 | $-0.09 | -96.89% |
| 2012 | $-2.89 | -1,096.55% |
| 2011 | $0.29 | -141.43% |
| 2010 | $-0.70 | 2.94% |
| 2009 | $-0.68 | -50.00% |
| 2008 | $-1.36 | 312.12% |
| 2007 | $-0.33 | -88.26% |
| 2006 | $-2.81 | -469.74% |
| 2005 | $0.76 | -40.16% |
| 2004 | $1.27 | 122.81% |
| 2003 | $0.57 | 23.91% |
| 2002 | $0.46 | -807.69% |
| 2001 | $-0.07 | -114.13% |
| 2000 | $0.46 | 0.00% |
EPS для аналогичных компаний или конкурентов
| Компания | EPS | Разница в EPS | Страна |
|---|---|---|---|
| $2.70 | 13.92% |
US
|
|
| $4.09 | 72.57% |
IE
|
|
| $9.45 | 298.73% |
US
|
|
| $2.21 | -6.84% |
DE
|
|
| $1.74 | -26.58% |
US
|
Вопросы и ответы: прибыль на акцию (EPS) компании Boston Scientific Corporation
Сколько составляет прибыль на акцию (EPS) компании Boston Scientific Corporation?
По состоянию на сент. 2026 прибыль на акцию (EPS) компании Boston Scientific Corporation за последние двенадцать месяцев составляет $2.37.
Сколько составляет прибыль на акцию (EPS) компании Boston Scientific Corporation по итогам 2025 года?
По итогам 2025 года прибыль на акцию (EPS) компании Boston Scientific Corporation — $1.96, на 55.56% больше, чем в 2024 году ($1.26).
Как меняется прибыль на акцию (EPS) компании Boston Scientific Corporation с 2020 года?
В 2020–2025 годах прибыль на акцию (EPS) компании Boston Scientific Corporation — от $-0.08 в 2020 году до $1.96 в 2025 году.
Как выглядит прибыль на акцию (EPS) компании Boston Scientific Corporation на фоне компаний-аналогов?
На фоне компаний-аналогов из приведённого списка прибыль на акцию (EPS) компании Boston Scientific Corporation ($2.37) выше, чем у 2 из 5. Наибольшее значение среди них — у Stryker Corporation ($9.45).